Literature DB >> 33970090

The Role of Cannabidiol in Neurological Disorders.

Sirichai Chayasirisobhon1.   

Abstract

None: Cannabis has been used for both recreational and medicinal purposes for more than 4 millennia. Cannabis has been studied in various medical disorders including neurological disorders. There are well-known risks of long-term use of cannabis, including low motivation, lowered cognitive capabilities, and diminished IQ and brain mass. Cannabinoids are compounds in cannabis that are known to have therapeutic potential. The most abundant chemicals in cannabinoids are delta-9-tetrahydrocannabinol and cannabidiol. Delta-9-tetrahydrocannabinol has psychotropic effects that limits its use as a pharmacotherapeutic agent. Cannabidiol is a nonpsychotropic chemical and therefore has become a compound of interest for clinical researchers to study its therapeutic potential. This article reviews the efficacy and safety of cannabidiol in various neurological disorders in humans.
Copyright © 2021 The Permanente Press. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33970090      PMCID: PMC8817911          DOI: 10.7812/TPP/20.156

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  44 in total

1.  Cannabidiol for the treatment of psychosis in Parkinson's disease.

Authors:  A W Zuardi; J A S Crippa; J E C Hallak; J P Pinto; M H N Chagas; G G R Rodrigues; S M Dursun; V Tumas
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

Review 2.  Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'.

Authors:  V Di Marzo; A Fontana
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1995-07       Impact factor: 4.006

Review 3.  Cannabis and epilepsy: An ancient treatment returns to the fore.

Authors:  Ethan B Russo
Journal:  Epilepsy Behav       Date:  2016-12-15       Impact factor: 2.937

4.  Interactions between cannabidiol and commonly used antiepileptic drugs.

Authors:  Tyler E Gaston; E Martina Bebin; Gary R Cutter; Yuliang Liu; Jerzy P Szaflarski
Journal:  Epilepsia       Date:  2017-08-06       Impact factor: 5.864

5.  Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial.

Authors:  D I Abrams; C A Jay; S B Shade; H Vizoso; H Reda; S Press; M E Kelly; M C Rowbotham; K L Petersen
Journal:  Neurology       Date:  2007-02-13       Impact factor: 9.910

6.  Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Elizabeth A Thiele; Eric D Marsh; Jacqueline A French; Maria Mazurkiewicz-Beldzinska; Selim R Benbadis; Charuta Joshi; Paul D Lyons; Adam Taylor; Claire Roberts; Kenneth Sommerville
Journal:  Lancet       Date:  2018-01-26       Impact factor: 79.321

7.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

Authors:  W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

8.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

9.  Short- and Long-Term Effects of Cannabis on Headache and Migraine.

Authors:  Carrie Cuttler; Alexander Spradlin; Michael J Cleveland; Rebecca M Craft
Journal:  J Pain       Date:  2019-11-09       Impact factor: 5.820

Review 10.  TRPV1 Channel: A Potential Drug Target for Treating Epilepsy.

Authors:  Mustafa Nazıroğlu
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

View more
  4 in total

Review 1.  Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders.

Authors:  Muhammad Yousaf; Dennis Chang; Yang Liu; Tianqing Liu; Xian Zhou
Journal:  Molecules       Date:  2022-08-04       Impact factor: 4.927

Review 2.  Review: Cannabinoids as Medicinals.

Authors:  Jag H Khalsa; Gregory Bunt; Kenneth Blum; Sanjay B Maggirwar; Marc Galanter; Marc N Potenza
Journal:  Curr Addict Rep       Date:  2022-09-07

3.  Neurogenetic and Epigenetic Aspects of Cannabinoids.

Authors:  Catherine A Dennen; Kenneth Blum; Abdalla Bowirrat; Jag Khalsa; Panayotis K Thanos; David Baron; Rajendra D Badgaiyan; Ashim Gupta; Eric R Braverman; Mark S Gold
Journal:  Epigenomes       Date:  2022-08-26

Review 4.  Role of Phytoconstituents as PPAR Agonists: Implications for Neurodegenerative Disorders.

Authors:  Anshul Sharma; Hae-Jeung Lee
Journal:  Biomedicines       Date:  2021-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.